tetano
Editor, Senior Moderator
Cell Rep Med
. 2020 Nov 17;1(8):100145.
doi: 10.1016/j.xcrm.2020.100145.
Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury
Neha Tabassum[SUP] 1 [/SUP], Hua Zhang[SUP] 2 [/SUP], Justin Stebbing[SUP] 1 [/SUP]
Affiliations
Abstract
A screen by Kost-Alimova et al.[SUP]1[/SUP] suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
. 2020 Nov 17;1(8):100145.
doi: 10.1016/j.xcrm.2020.100145.
Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury
Neha Tabassum[SUP] 1 [/SUP], Hua Zhang[SUP] 2 [/SUP], Justin Stebbing[SUP] 1 [/SUP]
Affiliations
- PMID: 33225317
- PMCID: PMC7670931
- DOI: 10.1016/j.xcrm.2020.100145
Abstract
A screen by Kost-Alimova et al.[SUP]1[/SUP] suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).